Co-Chairs, Benjamin M. Greenberg, MD, MHS, and Jiwon Oh, MD, PhD, FRCPC, discuss multiple sclerosis in this CME activity titled “BTK Inhibition as an MS Treatment Modality: Where Do We Stand and Where Are We Headed?.” For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/YCW865. CME credit will be available until March 23, 2024.
- Күн бұрын
BTK Inhibition as an MS Treatment Modality: Where Do We Stand and Where Are We Headed?
- Рет қаралды 1,084
Пікірлер